Increase in treatment compliance reveals new options of treatment of gastroesophageal reflux disease
Abstract
The aim of review. To present update on the causes of insufficient treatment response to proton pump inhibitors (PPI) at gastroesophageal reflux disease (GERD) and to inform on the options of increasing patients’ compliance.
Summary. Decline of treatment compliance remains to be one of the principal causes of refractory course of gastroesophageal reflux disease. Existing PPIs have some limitations — necessity of intake strictly before meal and short action period. Dexlansoprazole in double delayed release form allows intake without relation to food intake that allows to increase compliance to treatment.
Conclusion. The wide prevalence of GERD dictates necessity of search of new effective agents. Thus one of the principal causes of refractory course of disease is decreased adherence to treatment. Application of new PPI i.e. dexlansoprazole with once per day intake will allow to increase compliance to treatment and to reduce frequency and intensity of symptoms both at erosive esophagitis and non-erosive reflux disease.
About the Authors
Yu. V. Yevsyutina
State educational government-financed institution
of higher professional education «Sechenov First Moscow state medical university»
Russian Federation
Russian Federation
Yevsyutina Yuliya V. — post-graduate student, Chair of internal diseases propedeutics, medical faculty
119991, Moscow, Pogodinskaya street, 1, bld 1.
A. S. Trukhmanov
State educational government-financed institution
of higher professional education «Sechenov First Moscow state medical university»
Russian Federation
Russian Federation
Trukhmanov Aleksandr S. — MD, PhD, professor of the Chair of internal diseases propedeutics, medical faculty
119991, Moscow, Pogodinskaya street, 1, bld. 1.
References
1. Ивашкин В.Т., Маев И.В., Трухманов А.С., Баранская Е.К., Дронова О.Б. и др. Гастроэзофагеальная рефлюксная болезнь. Клинические рекомендации. М., 2013:22 с.
2. Ивашкин В.Т., Трухманов А.С. Эволюция представлений о роли нарушений двигательной функции пищевода в патогенезе гастроэзофагеальной рефлюксной болезни. Рос журн гастроэнтерол гепатол колопроктол 2010; 20(2):13-9.
3. Инструкция по применению лекарственного препарата для медицинского применения Дексилант®. Рег. уд. ЛП 002477-260514.
4. Лазебник Л.Б., Бордин Д.С., Машарова А.А., Джулай Г.С., Бутов М.А., Абдулхаков Р.А., Еремина Е.Ю., Тарасова Л.В., Сафонова О.В., Фирсова Л.Д., Кожурина Т.С. Восстановление качества жизни устранением и предотвращением изжоги алгинатом: результаты многоцентрового исследования ВИА АПИА. Эксперим клин гастроэнтерол 2010; 6:70-6.
5. Маев И.В., Андреев Д.И., Дичева Д.Т. Гастроэзофагеальная рефлюксная болезнь: от патогенеза к терапевтическим аспектам. Consilium medicum 2013; 15(8):30-4.
6. Маев И.В., Вьючкова Е.С., Щекина М.И. Гастроэзофагеальная рефлюксная болезнь — болезнь XXI века. Лечащий врач 2004; 4:10-4.
7. Сторонова О.А., Трухманов А.С., Джахая Н.Л. Нарушения пищеводного клиренса при гастроэзофагеальной рефлюксной болезни и возможности их коррекции. Рос журн гастроэнтерол гепатол колопроктол 2012; 22(2):14-21.
8. Трухманов А.С., Джахая Н.Л., Кайбышева В.О., Сторонова О.А. Новые аспекты рекомендаций по лечению больных гастроэзофагеальной рефлюксной болезнью. Гастроэнтерол гепатол 2013; 1(4):1-9.
9. Шептулин А.А. Современные возможности и перспективы лечения резистентных форм гастроэзофагеальной рефлюксной болезни. Рос журн гастроэнтерол гепатол колопроктол 2010; 20(6):81-5.
10. Bell N.J.V., Burget D., Howden C.W., et al. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 51:59-67.
11. Bergstrand R., Grind M., Nyberg G., Olafsson B. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standard breakfast. Clin Drug Invest 1995; 9:67-71.
12. Boulanger L., Mody R., Bao Y., Kothari S., Russell M.W. Does the dosing frequency of proton pump inhibitors (PPIs) affect medication adherence among patients diagnosed with gastroesophageal reflux disease (GERD)? Gastroenterology 2008; 134 (Suppl 1):321-2.
13. Dabholkar A.H., et al. The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastroesophageal reflux disease. Aliment Pharmacol Ther 2011; 33:366-77.
14. Chang P., Friedenberg F. Obesity and GERD. Gastroenterol Clin 2014; 43:161-73.
15. Chey W.D., Inadomi J.M., Booher A.M., Sharma V.K., Fendrick A.M., Howden C.W. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol 2005; 100:1237-42.
16. Chey W.D., Mody R.R., Wu E.Q., Chen L., Kothari S., Persson B., Beaulieu N., Lu M. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin 2009; 25(8):1869-78.
17. Cicala M., Emerenziani S., Guarino M.P., Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol 2013; 19(39):6529-35.
18. Dean B.B., Gano A.D. Jr., Knight K., et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656-64.
19. Delhotal-Landes B., Cournot A., Vermerie N., Dellatolas F., Benoiot M., Flouvat B. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991; 3:315-20.
20. Dellon E., Shaheen N. Persistent reflux symptoms in the proton pump inhibitor era: The changing face of gastroesophageal reflux disease. Gastroenterology 2010; 139:7-13.
21. DeVault K.R., Castell D.O. Updated guideines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100:190-200.
22. Donnellan C., Sharma N., Preston C., Moayyedi P. Medical treatments for the maintenance therapy of reflux esophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2004: CD003245.
23. El-Serag H.B., Sweet S., Winchester C.C., Dent J. Update on the epidemiology of gastroesophageal reflux disease: a systematic review. Gut 2014; 63(6):871-80.
24. Fass R., Chey W.D., Zakko S.F., Andhivarothai N., Palmer R.N., Perez M.C., Atkinson S.N. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2009; 29:1261-72.
25. Fass R., Ofman J.J. Gastroesophageal reflux disease — should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97:1901-9.
26. Fass R., Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002; 51:885-92.
27. Fornari F., Blondeau K., Mertens V., Tack J., Sifrim D. Nocturnal gastroesophageal reflux revisited by impedance-pH monitoring. J Neurogastroenterol Motil 2011; 17:148-59.
28. Gunaratnam N.T., Jessup T.P., Inadomi J., Lascewski D.P. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastrooesophageal reflux disease. Aliment Pharmacol Ther 2006; 23:1473-7.
29. Katz P., Gerson L., Vela M. Guidelines for the diagnosis and management of gastroesophageal refl ux disease. Am J Gastroenterol 2013; 108:308-28.
30. Keski-Rahkonen A., Kaprio J., Rissanen A., Virkkunen M., Rose R.J. Breakfast skipping and healthcompromising behaviors in adolescents and adults. Eur J Clin Nutr 2003; 57:842-53.
31. Kukulka M., Eisenberg C., Nudurupati S. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayedrelease esomeprazole 40 mg. Clin Exp Gastroenterol 2011; 4:213-20.
32. Lagergren J., Bergström R., Lindgren A. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340:825-31.
33. Lee R.D., Vakily M., Mulford D., Wu J., Atkinson S.N. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor — evidence for dosing flexibility. Aliment Pharmacol Ther 2009; 29:824-33.
34. Metz D.C., Howden C.W., Perez M.C., Larsen L., O’Neil J., Atkinson S.N. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive esophagitis. Aliment Pharmacol Ther 2009; 29:742-54.
35. Metz D.C., Vakily M., Dixit T., Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009; 29:928-37.
36. Nexium (esomeprazole magnesium). Full prescribing information. Wilmington, DE: AstraZeneca LP, 2010.
37. Persson K. When do ulcer patients take their acid inhibiting medication? Hassle Information 1993; 7:19-23.
38. Peura D.A., Pilmer B., Hunt B., Mody R., Perez M.C. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Aliment Pharmacol Ther 2013; 37(8):810-8.
39. Prevacid (lansoprazole). Full prescribing information. Lake Forest, IL: TAP Pharmaceutical Products, Inc., 2008.
40. Prilosec (omeprazole). Full prescribing information. Wilmington, DE: AstraZeneca LP, 2008.
41. Sachs G., Shin J.M., Briving C., Wallmark B., Hersey S. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annu Rev Pharmacol Toxicol 1995; 35:277-305.
42. Sharma P., Shaheen N.J., Perez M.C., Pilmer B.L., Lee M., Atkinson S.N., Peura D. Clinical trials: healing of erosive esophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation — results from two randomized controlled studies. Aliment Pharmacol Ther 2009; 29:731-41.
43. Sostek M.B., Chen Y., Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol 2007; 64:386-90.
44. Vaz-da-Silva M., Loureiro A.I., Nunes T. Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions. Clin Drug Invest 2005; 25:391-9.
45. Wu J.C., Lai L.H., Chow D.K., Wong G.L., Sung J.J., Chan F.K. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastroesophageal reflux disease. Neurogastroenterol Motil 2011; 23(2):155-60.
Review
For citations:
Yevsyutina Yu.V., Trukhmanov A.S. Increase in treatment compliance reveals new options of treatment of gastroesophageal reflux disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(2):4-9. (In Russ.)
Views:
140
Email this article 
